Cefepime 2g IV BID in 100 mL NS Over 30 Minutes: Appropriate Dosing
Yes, administering cefepime 2 g intravenously twice daily (every 12 hours) diluted in 100 mL of normal saline over a 30-minute infusion is appropriate and aligns with FDA-approved dosing for most indications in patients with normal renal function.
FDA-Approved Administration
The FDA label explicitly states that cefepime should be "administered intravenously over approximately 30 minutes" 1. The 2 g dose every 12 hours is the standard regimen for:
- Moderate to severe pneumonia (including Pseudomonas aeruginosa)
- Severe urinary tract infections
- Uncomplicated skin and skin structure infections
- Complicated intra-abdominal infections (when combined with metronidazole) 1
Multiple clinical practice guidelines support this dosing strategy. For complicated intra-abdominal infections, both IDSA/SIS 2 and WSES 3 guidelines recommend cefepime 2 g every 8-12 hours. For hospital-acquired and ventilator-associated pneumonia, IDSA/ATS guidelines recommend cefepime 2 g IV every 8 hours, though every 12 hours dosing is acceptable for less severe infections 4.
Volume and Diluent Considerations
The 100 mL volume of normal saline is appropriate. The FDA label does not specify a minimum or maximum dilution volume, but 100 mL for a 2 g dose (20 mg/mL concentration) is standard practice and well within safe concentration ranges 1. Normal saline is the preferred diluent—the FDA label specifically recommends normal saline for fluid replacement in critically ill patients and does not contraindicate it as a diluent 1.
Critical Dosing Adjustments
Renal Impairment
This dosing is ONLY appropriate for patients with creatinine clearance >60 mL/min. For CrCl 30-60 mL/min, reduce to 2 g every 24 hours. For CrCl 11-29 mL/min, reduce to 1 g every 24 hours 1. Failure to adjust dosing in renal impairment significantly increases neurotoxicity risk 5, 6.
Higher-Dose Scenarios
For severe Pseudomonas aeruginosa infections or febrile neutropenia, the FDA recommends 2 g every 8 hours (not 12 hours) 1. Recent guidelines for critically ill patients with healthcare-associated infections also support every 8-hour dosing 3, 4.
Pharmacokinetic/Pharmacodynamic Optimization
Consider extended or continuous infusion for critically ill patients or infections with pathogens having MIC ≥4 mg/L. French critical care guidelines 7 and recent research 8, 9 suggest that extended infusions (3-hour infusion of 1 g every 6 hours, total 4 g/day) or continuous infusion may improve outcomes while reducing drug costs and neurotoxicity risk. Standard intermittent dosing maintains concentrations above MIC for ≥70% of the dosing interval only when MIC ≤4 mg/L 5, 10.
Neurotoxicity Warning
Monitor closely for neurotoxicity, especially in patients ≥65 years old or with any degree of renal impairment. Cefepime-induced neurotoxicity (encephalopathy, confusion, myoclonus, seizures, non-convulsive status epilepticus) can occur even with appropriate dose adjustments 1, 6. The ACORN trial found cefepime recipients had 21% fewer delirium- and coma-free days compared to piperacillin-tazobactam 6. Discontinue cefepime immediately if neurotoxicity occurs.
Common Pitfalls to Avoid
- Do not use this dosing in renal impairment (CrCl ≤60 mL/min) without adjustment
- Do not use every 12-hour dosing for febrile neutropenia—use every 8 hours 1
- Do not assume adequate coverage for pathogens with MIC ≥8 mg/L with standard dosing—consider higher doses or alternative agents 5, 11
- Do not overlook subtle neurologic symptoms (confusion, muscle jerks) as these may represent cefepime toxicity requiring immediate discontinuation 5, 6